Nonalcoholic fatty liver disease in patients with polycystic ovary syndrome

Cover Page

Cite item

Full Text

Abstract

The article provides an overview of the current literature on the problem of polycystic ovary syndrome (PCOS) and non-alcoholic fatty liver disease (NAFLD). The prevalence of NAFLD in women with PCOS, substantially higher compared with the general population. Among the reasons for the high comorbidity of these disorders is common pathogenetic pathways, including insulin resistance, obesity, and metabolic syndrome. Formation of NAFLD in women with PCOS at a younger age and earlier progression of changes in the liver than in the general population are unfavorable prognostic factors. The presented results of authors own observations confirm the high prevalence of NAFLD in patients with PCOS, its association with obesity, lipid metabolism disorders and adipokines. The remedies of female sex steroid using in patients with PCOS and NAFLD is associated with the risk of drug liver injury therefore liver condition requires monitoring prior to and during the treatment period.

About the authors

Yu. B Uspenskaya

I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation

Email: jusp@mail.ru
канд. мед. наук, вед. науч. сотр. научно-исследовательского отд. женского здоровья НИЦ ГБОУ ВПО Первый МГМУ им. И.М.Сеченова 119991, Russian Federation, Moscow, ul. Trubetskaia, d. 8, str. 2

I. V Kuznetsova

I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation

д-р мед. наук, проф., гл. науч. сотр. научно-исследовательского отд. женского здоровья НИЦ ГБОУ ВПО Первый МГМУ им. И.М.Сеченова 119991, Russian Federation, Moscow, ul. Trubetskaia, d. 8, str. 2

E. R Vedzizheva

I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation

аспирант научно-исследовательского отд. женского здоровья НИЦ ГБОУ ВПО Первый МГМУ им. И.М.Сеченова 119991, Russian Federation, Moscow, ul. Trubetskaia, d. 8, str. 2

References

  1. Буеверов А.О. Возможности лечения лекарственных поражений печени в условиях необходимости приема гепатотоксичных препаратов. Лечащий врач. 2009; 2: 40-2.
  2. Никитин И.Г. Скрининговая программа по выявлению распространенности неалкогольной жировой болезни печени и определению факторов риска развития заболевания. Рос. мед. вести. 2010; 4 (1): 41-6.
  3. Руководство по амбулаторно - поликлинической помощи в акушерстве и гинекологии. Под ред. В.Е.Радзинского. 2-е изд., перераб. и доп. М.: ГЭОТАР-Медиа, 2014.
  4. Руководство по репродуктивной медицине. Под ред. Б.Карра, Р.Блэкуэлла, Р.Азиза. Пер. с англ. М.: Практика, 2015.
  5. Abdelmalek M.F, Diehl A.M. Nonalcoholic fatty liver disease as a complication of insulin resistance. Med Clin North Am 2007; 91: 1125-49.
  6. Adams L.A, Lymp J.F, St Sauver J et al. The natural history of nonalcoholic fatty liver disease: a population - based cohort study. Gastroenterology 2005; 129: 113-21.
  7. Agacayak E, Tunc S.Y, Sak S et al. Levels of Neopterin and other Inflammatory Markers in Obese and Non-Obese Patients with Polycystic Ovary Syndrome. Med Sci Monit 2015; 21: 2446-55.
  8. Alvarez-Blasco F, Botella-Carretero J.I, San Millán J.L, Escobar-Morreale H.F. Prevalence and characteristics of the polycystic ovary syndrome in overweight and obese women. Arch Intern Med 2006; 166: 2081-6.
  9. American Association of Clinical Endocrinologists. American Association of Clinical Endocrinologists position statement on metabolic and cardiovascular consequences of polycystic ovary syndrome. National Guideline Clearinghouse. Available at http://guideline.gov/summary/summary.aspx?doc_id=7108. Accessed: August 28, 2009.
  10. Angulo P, Alba L.M, Petrovic L.M et al. Leptin, insulin resistance, and liver fibrosis in human nonalcoholic fatty liver disease. J Hepatol 2004; 41 (6): 943-9.
  11. Awartani K.A, Cheung A.P. Metformin and polycystic ovary syndrome: a literature review. J Obstet Gynaecol Can 2002; 24 (5): 393-401.
  12. Azziz R, Woods K.S, Reyna R et al. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004; 89: 2745-9.
  13. Azziz R, Dumesic D.A, Goodarzi M.O. Polycystic ovary syndrome: an ancient disorder? Fertil Steril 2011; 95: 1544-8.
  14. Bantel H, Ruck P, Gregor M, Schulze-Osthoff K. Detection of elevated caspase activation and early apoptosis in liver diseases. Eur J Cell Biol 2001; 80: 230-9.
  15. Baranova A, Tran T.P, Afendy A et al. Molecular signature of adipose tissue in patients with both nonalcoholic fatty liver disease (NAFLD) and polycystic ovarian syndrome (PCOS). J Transl Med 2013; 11: 133.
  16. Baranova A, Tran T.P, Birerdinc A, Younossi Z.M. Systematic review: association of polycystic ovary syndrome with metabolic syndrome and non - alcoholic fatty liver disease. Aliment Pharmacol Ther 2011; 33: 801-4.
  17. Barber T.M, Franks S. Genetics of polycystic ovary syndrome. Front Horm Res 2013; 40: 28-39.
  18. Brower M.A, Jones M.R, Rotter J.I et al. Further investigation in Europeans of susceptibility variants for polycystic ovary syndrome discovered in genome - wide association studies of Chinese individuals. J Clin Endocrinol Metab 2015; 100: 182-6.
  19. Brzozowska M.M, Ostapowicz G, Weltman M.D. An association between non - alcoholic fatty liver disease and polycystic ovarian syndrome. J Gastroenterol Hepatol 2009; 24: 243-7.
  20. Bugianesi E, Gastaldelli A, Vanni E et al. Insulin resistance in non - diabetic patients with non - alcoholic fatty liver disease: sites and mechanisms. Diabetologia 2005; 48 (4): 634-42.
  21. Cadranel J.F, Rufat P, Degos F. Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology 2000; 32: 477-81.
  22. Cankaya S, Demir B, Aksakal S.E et al. Insulin resistance and its relationship with high molecular weight adiponectin in adolescents with polycystic ovary syndrome and a maternal history of polycystic ovary syndrome. Fertil Steril 2014; 102: 826-30.
  23. Cerda C, Perez-Ayuso R.M, Riquelme A et al. Nonalcoholic fatty liver disease in women with polycystic ovary syndrome. J Hepatol 2007; 47 (3): 412-7.
  24. Chalasani N, Younossi Z, Lavine J.E et al. The diagnosis and management of non - alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012; 55: 2005-23.
  25. Chang R.J, Nakamura R.M, Judd H.L, Kaplan S.A. Insulinresistance in nonobese patients with polycystic ovarian disease. J Clin Endocrinol Metab 1983; 57: 356-9.
  26. Ciotta L, Pagano I, Stracquadanio M, Formuso C. Polycystic ovarian syndrome incidence in young women with non - alcoholic fatty liver disease. Minerva Ginecol 2011; 63: 429-37.
  27. Cusi K, Charlton M, Sanyal A.J. The diagnosis and management of non - alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012; 55: 2005-23.
  28. Cussons A.J, Watts G.F, Mori T.A, Stuckey B.G. Omega-3 fatty acid supplementation decreases liver fat content in polycystic ovary syndrome: a randomized controlled trial employing proton magnetic resonance spectroscopy. J Clin Endocrinol Metab 2009; 94: 3842-8.
  29. Diamanti-Kandarakis E, Christakou C.D. Insulin Resistance in PCOS. Springer, 2009.
  30. Diamanti-Kandarakis E. Insulin resistance in PCOS. Endocrine 2006; 30 (1): 13-7.
  31. Dunaif A, Graf M, Mandeli J et al. Characterization of groups of hyperandrogenic women with acanthosis nigricans, impaired glucose tolerance, and/or hyperinsulinemia. J Clin Endocrinol Metab 1987; 65: 499-507.
  32. Dunaif A, Segal K.R, Shelley D.R et al. Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome. Diabetes 1992; 41: 1257-66.
  33. Dunaif A. Drug insight: insulin - sensitizing drugs in the treatment of polycystic ovary syndrome - a reappraisal. Nat Clin Pract Endocrinol Metab 2008; 4: 272-83.
  34. Economou F, Xyrafis X, Livadas S et al. In overweight/obese but not in normal - weight women, polycystic ovary syndrome is associated with elevated liver enzymes compared to controls. Hormones (Athens) 2009; 8: 199-206.
  35. El-Mazny A, Abou-Salem N, El-Sherbiny W, El-Mazny A. Insulin resistance, dyslipidemia, and metabolic syndrome in women with polycystic ovary syndrome. Int J Gynaecol Obstet 2010; 109: 239-41.
  36. Feldstein A.E, Wieckowska A, Lopez A.R et al. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology 2009; 50: 1072-8.
  37. Gambarin-Gelwan M, Kinkhabwala S.V, Schiano T.D et al. Prevalence of nonalcoholic fatty liver disease in women with polycystic ovary syndrome. Clin Gastroenterol Hepatol 2007; 5: 496-501.
  38. Gangale M.F, Miele L, Lanzone A et al. Long - term metformin treatment is able to reduce the prevalence of metabolic syndrome and its hepatic involvement in young hyperinsulinaemic overweight patients with polycystic ovarian syndrome. Clin Endocrinol (Oxf) 2011; 75: 520-7.
  39. Gao T, Wu L, Chang F, Cao G. Low circulating ghrelin levels in women with polycystic ovary syndrome: a systematic review and meta - analysis. Endocr J 2016; 63 (1): 93-100.
  40. Gauna C, van der Lely A.J. Somatostatin, cortistatin, ghrelin and glucose metabolism. J Endocrinol Invest 2005; 28: 127-31.
  41. Goldman M.H, Scheraldi C.A, Soule W.C. Ovarian hyperthecosis associated with fatty liver disease. Am J Obstet Gynecol 1987; 156: 1239-40.
  42. Gomez-Meade C.A, Lopez-Mitnik G, Messiah S.E et al. Cardiometabolic health among gastric bypass surgery patients with polycystic ovarian syndrome. World J Diabetes 2013; 4: 64-9.
  43. Gonzalez F, Sia C.L, Bearson D.M, Blair H.E. Hyperandrogenism induces a proinflammatory TNFa response to glucose ingestion in a receptor - dependent fashion. Endocrine J Clin Endocrinol Metab 2016; 51: 211-21.
  44. Goodman N.F, Cobin R.H, Futterweit W et al. American Association of Clinical Endocrinologists, American College of Endocrinology, and Androgen Excess and PCOS Society disease state clinical review: guide to the best practices in the evaluation and treatment of polycystic ovary syndrome - part 1. Endocr Pract 2015; 21 (11): 1291-300.
  45. Goverde A.J, van Koert A.J, Eijkemans M.J et al. Indicators for metabolic disturbances in anovulatory women with polycystic ovary syndrome diagnosed according to the Rotterdam consensus criteria. Hum Reprod 2009; 24: 710-7.
  46. Harrison S.A, Torgerson S, Hayashi P.H. The natural history of nonalcoholic fatty liver disease: a clinical histopathological study. Am J Gastroenterol 2003; 98: 2042-7.
  47. Jamali R. Non - Alcoholic Fatty Liver Disease. Walter Siegenthaler, 2013.
  48. Kadowaki T, Yamauchi T, Kubota N et al. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 2006; 116: 1784-92.
  49. Kauffman R.P, Baker T.E, Baker V et al. Endocrine factors associated with non - alcoholic fatty liver disease in women with polycystic ovary syndrome: do androgens play a role? Gynecol Endocrinol 2010; 26: 39-46.
  50. Kojima M, Hosoda H, Date Y et al. Ghrelin is a growth - hormone - releasing acylated peptide from stomach. Nature 1999; 402: 656-60.
  51. Kola B, Hubina E, Tucci S.A et al. Cannabinoids and ghrelin have both central and peripheral metabolic and cardiac effects via AMP-activated protein kinase. J Biol Chem 2005; 280: 25196-201.
  52. Komarowska H, Wasko R, Iwanik K et al. Ghrelin ovarian cell expression in patients with polycystic ovary syndrome: animmunohistochemical evaluation. Horm Metab Res 2006; 38: 783-8.
  53. Lee Y.H, Pratley R.E. The evolving role of inflammation in obesity and the metabolic syndrome. Curr Diab Rep 2005; 5: 70-5.
  54. Legro R.S, Arslanian S.A, Ehrmann D.A et al. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2013; 98: 4565-92.
  55. Lerchbaum E, Gruber H.J, Schwetz V et al. Fatty liver index in polycystic ovary syndrome. Eur J Endocrinol 2011; 165: 935-43.
  56. Li Y, Hai J, Li L et al. Administration of ghrelin improves inflammation, oxidative stress, and apoptosis during and after non - alcoholic fatty liver disease development. Endocrine 2013; 43: 376-86.
  57. Loria P, Carulli L, Bertolotti M, Lonardo A. Endocrine and liver interaction: the role of endocrine pathways in NASH. Nat Rev Gastroenterol Hepatol 2009; 6 (4): 236-47.
  58. Macut D, Tziomalos K, Božić-Antić I et al. Non - alcoholic fatty liver disease is associated with insulin resistance and lipid accumulation product in women with polycystic ovary syndrome. Hum Reprod 2016. pii: dew076.
  59. Mao Y, Cheng J, Yu F et al. Ghrelin Attenuated Lipotoxicity via Autophagy Induction and Nuclear Factor-κB Inhibition. Cell Physiol Biochem 2015; 37 (2): 563-76.
  60. March W.A, Moore V.M, Willson K.J et al. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod 2010; 25: 544-51.
  61. Marchesini G, Brizi M, Morselli-Labate A.M et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999; 107 (5): 450-5.
  62. Mitkov M, Pehlivanov B, Orbetzova M. Serum ghrelin level in women with polycystic ovary syndrome and its relationship with endocrine and metabolic parameters. Gynecol Endocrinol 2008; 24: 625-30.
  63. Murata M, Okimura Y, Iida K et al. Ghrelin modulates the downstream molecules of insulin signaling in hepatoma cells. J Biol Chem 2002; 277: 5667-74.
  64. Myers R.P, Fong A, Shaheen A.A. Utilization rates, complications and costs of percutaneous liver biopsy: a population - based study including 4275 biopsies. Liver Int 2008; 28: 705-12.
  65. Mykhalchyshyn G, Kobyliak N, Bodnar P. Diagnostic accuracy of acyl - ghrelin and it association with non - alcoholic fatty liver disease in type 2 diabetic patients. J Diabetes Metab Disord 2015; 14: 44.
  66. Nakazato M, Murakami N, Date Y et al. A role for ghrelin in the central regulation of feeding. Nature 2001; 409: 194-8.
  67. Nehir Aytan A, Bastu E, Demiral I et al. Relationship between hyperandrogenism, obesity, inflammation and polycystic ovary syndrome. Gynecol Endocrinol 2016 Mar 7: 1-5.
  68. O’Reilly M.W, Taylor A.E, Crabtree N.J et al. Hyperandrogenemia predicts metabolic phenotype in polycystic ovary syndrome: the utility of serum androstenedione. J Clin Endocrinol Metab 2014; 99: 1027-36.
  69. Ozturk Z.A, Kadayifci A. Insulin sensitizers for the treatment of nonalcoholic fatty liver disease. World J Hepatol 2014; 6 (4): 199-206.
  70. Panidis D, Tziomalos K, Misichronis G et al. Insulin resistance and endocrine characteristics of the different phenotypes of polycystic ovary syndrome: a prospective study. Hum Reprod 2012; 27: 541-9.
  71. Parker H.M, Johnson N.A, Burdon C.A et al. Omega-3 supplementation and non - alcoholic fatty liver disease: a systematic review and meta - analysis. J Hepatol 2012; 56: 944-51.
  72. Pasquali R, Casimirri F, Venturoli S et al. Body fat distribution has weight - independent effects on clinical, hormonal, and metabolic features of women with polycystic ovary syndrome. Metabolism 1994; 43: 706-13.
  73. Prati D, Taioli E, Zanella A et al. Updated definitions of healthy ranges for serum alanine minotransferase levels. Ann Intern Med 2002; 137: 1-10.
  74. Preiss D, Sattar N, Harborne L et al. The effects of 8 months of metformin on circulating GGT and ALT levels in obese women with polycystic ovarian syndrome. Int J Clin Pract 2008; 62: 1337-43.
  75. Qu Z, Zhu Y, Jiang J et al. The clinical characteristics and etiological study of nonalcoholic fatty liver disease in Chinese women with PCOS. Iran J Reprod Med 2013; 11 (9): 725-32.
  76. Ramezani-Binabaj M, Motalebi M, Karimi-Sari H et al. Are women with polycystic ovarian syndrome at a high risk of non - alcoholic Fatty liver disease; a meta - analysis. Hepat Mon 2014; 14 (11): e23235.
  77. Randeva H.S, Tan B.K, Weickert M.O et al. Cardiometabolic aspects of the polycystic ovary syndrome. Endocr Rev 2012; 33: 812-41.
  78. Rodríguez A, Gómez-Ambrosi J, Catalán V et al. Acylated and desacyl ghrelin stimulate lipid accumulation in human visceral adipocytes. Int J Obes (Lond) 2009; 33: 541-52.
  79. Ronti T, Lupattelli G, Mannarino E. The endocrine function of adipose tissue: an update. Clin Endocrinol (Oxf) 2006; 64: 355-65.
  80. Rosenfield R.L. Clinical review: adolescent anovulation: maturational mechanisms and implications. J Clin Endocrinol Metab 2013; 98: 3572-83.
  81. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteriaand long - term health risks related to polycystic ovary syndrome. Fertil Steril 2004; 81: 19-25.
  82. Saadeh S, Younossi Z.M, Remer E.M et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002; 123 (3): 745-50.
  83. Schwimmer J.B, Khorram O, Chiu V, Schwimmer W.B. Abnormal aminotransferase activity in women with polycystic ovary syndrome. Fertil Steril 2005; 83: 494-7.
  84. Setji T.L, Holland N.D, Sanders L.L et al. Nonalcoholic steatohepatitis and nonalcoholic Fatty liver disease in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 2006; 91: 1741-7.
  85. Siegelman E.S, Rosen M.A. Imaging of hepatic steatosis. Semin Liver Dis 2001; 21 (1): 71-80.
  86. Sirmans S.M, Pate K.A. Epidemiology, diagnosis, and management of polycystic ovary syndrome. Clin Epidemiol 2013; 6: 1-13.
  87. Syn W.K, Choi S.S, Diehl A.M. Apoptosis and cytokines in non - alcoholic steatohepatitis. Clin Liver Dis 2009; 13: 565-80.
  88. Tan S, Bechmann L.P, Benson S et al. Apoptotic markers indicate nonalcoholic steatohepatitis in polycystic ovary syndrome. J Clin Endocrinol Metab 2010; 95: 343-8.
  89. Targher G, Bertolini L, Scala L et al. Decreased plasma adiponectin concentrations are closely associated with nonalcoholic hepatic steatosis in obese individuals. Clin Endocrinol (Oxf) 2004; 61: 700-3.
  90. Targher G, Solagna E, Tosi F et al. Abnormal serum alanine aminotransferase levels are associated with impaired insulin sensitivity in young women with polycystic ovary syndrome. J Endocrinol Invest 2009; 32: 695-700.
  91. Thoma C, Day C.P, Trenell M.I. Lifestyle interventions for the treatment of non - alcoholic fatty liver disease in adults: a systematic review. J Hepatol 2012; 56: 255-66.
  92. Tong J, Prigeon R.L, Davis H.W et al. Ghrelin suppresses glucose - stimulated insulin secretion and deteriorates glucose tolerance in healthy humans. Diabetes 2010; 59: 2145-51.
  93. Toulis K.A, Goulis D.G, Farmakiotis D et al. Adiponectin levels in women with polycystic ovary syndrome: a systematic review and a meta - analysis. Hum Reprod Update 2009; 15 (3): 297-307.
  94. Tziomalos K, Athyros V.G, Karagiannis A. Non - alcoholic fatty liver disease in type 2 diabetes: pathogenesis and treatment options. Curr Vasc Pharmacol 2012; 10: 162-72.
  95. Utzschneider K.M, Kahn S.E. Review: The role of insulin resistance in nonalcoholic fatty liver disease. J Clin Endocrinol Metab 2006; 91 (12): 4753-61.
  96. Van der Lely A.J, Tschop M, Heiman M.L, Ghigo E. Biological, physiological, pathophysiological, and pharmacological aspects of ghrelin. Endocr Rev 2004; 25: 426-57.
  97. Vassilatou E, Lafoyianni S, Vryonidou A et al. Increased androgen bioavailability is associated with non - alcoholic fatty liver disease in women with polycystic ovary syndrome. Hum Reprod 2010; 25: 212-20.
  98. Vassilatou E. Nonalcoholic fatty liver disease and polycystic ovary syndrome. World J Gastroenterol 2014; 20 (26): 8351-63.
  99. Vernon G, Baranova A, Younossi Z.M. Systematic review: the epidemiology and natural history of non - alcoholic fatty liver disease and non - alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011; 34: 274-85.
  100. Wieckowska A, Mc Cullough A.J, Feldstein A.E. Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future. Hepatology 2007; 46: 582-9.
  101. Younossi Z.M, Reyes M.J, Mishra A et al. Systematic review with meta - analysis: non - alcoholic steatohepatitis - a case for personalised treatment based on pathogenic targets. Aliment Pharmacol Ther 2014; 39: 3-14.
  102. Zueff L.F, Martins W.P, Vieira C.S, Ferriani R.A. Ultrasonographic and laboratory markers of metabolic and cardiovascular disease risk in obese women with polycystic ovary syndrome. Ultrasound Obstet Gynecol 2012; 39 (3): 341-7.

Copyright (c) 2016 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies